Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

類似資料

• Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
  著者:: Kaufman, Bella, 等
  出版事項: (2008)
• Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor–Positive Metastatic Breast Cancer
  著者:: Schwartzberg, Lee S., 等
  出版事項: (2010)
• A Pooled Analysis of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer
  著者:: Seidman, Andrew D., 等
  出版事項: (2014)
• Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
  著者:: Saura, Cristina, 等
  出版事項: (2020)
• Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
  著者:: Sherrill, Beth, 等
  出版事項: (2010)